Detalhe da pesquisa
1.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
N Engl J Med
; 390(10): 875-888, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38446675
2.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(7): 931-945, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051178
3.
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.
Proc Natl Acad Sci U S A
; 114(52): 13679-13684, 2017 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29229836
4.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
N Engl J Med
; 375(9): 819-29, 2016 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27433843
5.
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
J Clin Oncol
; 41(25): 4107-4117, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369081
6.
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Clin Cancer Res
; 28(10): 2050-2060, 2022 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247908
7.
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Clin Genitourin Cancer
; 19(1): e17-e30, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32826180
8.
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
J Immunother Cancer
; 9(4)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33879601
9.
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.
J Clin Oncol
; 38(23): 2658-2666, 2020 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32552471
10.
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Clin Cancer Res
; 26(19): 5086-5091, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32605909
11.
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
JAMA Oncol
; 6(8): 1256-1264, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32672795
12.
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
J Clin Oncol
; 37(9): 693-702, 2019 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30726175
13.
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Clin Cancer Res
; 24(8): 1805-1815, 2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29358500
14.
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
Oncoimmunology
; 5(7): e1052212, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27622011
15.
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Cancer Immunol Res
; 4(10): 845-857, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27589875
16.
Excluding T Cells: Is ß-Catenin the Full Story?
Cancer Cell
; 27(6): 749-50, 2015 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26058073
17.
Anti-PD-1 therapy in melanoma.
Semin Oncol
; 42(3): 466-73, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25965365
18.
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Sci Transl Med
; 7(279): 279ra41, 2015 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25787767
19.
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
J Clin Oncol
; 32(21): 2248-54, 2014 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24958825
20.
Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.
Clin Transl Oncol
; 12(7): 468-72, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20615823